The relationship between oestrogen receptor-alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer Aims: Although the role of phosphorylation of oestrogen receptor (ER) at serines 118 (p-S118) and 167 (p-S167) has been studied, the relationship between p-S118, p-S167 and the tumour microenvironment in ER-positive primary operable ductal breast cancers have not been investigated. The aims of this study are to investigate (i) the relationship between p-S118/p-S167 and the tumour microenvironment, and (ii) the effect of p-S118/167 on survival and recurrence in ER-positive primary operable ductal breast cancers. Methods and results: Patients presenting at three Glasgow hospitals between 1995 and 1998 with invasive ductal ER-positive primary breast cancers were studied (n = 294). Immunohistochemical staining of p-S118 and p-S167 was performed and their association with clinicopathological characteristics, cancer-specific survival (CSS) and recurrence-free interval (RFI) were examined. In the whole cohort, tumour size (P < 0.05) and microvessel density (P < 0.05) were associated with high p-S118 while increased micovessel density (P < 0.05), apoptosis (P < 0.05), general inflammatory infiltrate measured using the Klintrup-Makinen score (P < 0.05) and macrophage infiltrate (P < 0.05) were found to be associated with high p-S167. Only high p-S167 was associated with shorter CSS (P < 0.005) and shorter RFI in the whole cohort (P = 0.001) and separately in the luminal A (P < 0.05) and B tumours (P < 0.05). Conclusions: This study showed that both p-S118 and p-S167 were associated with several microenvironmental factors, including increased microvessel density. In particular, p-S167 was associated with reduced RFI and CSS in the whole cohort and RFI in luminal A and B tumours and could possibly be employed to predict response to kinase inhibitors.
Introduction
Breast cancer, which accounts for 30% of new incidences of cancer in females, is the most common cancer in the United Kingdom. With improved treatment modalities, the survival rate has increased significantly, with 78.4% patients having 10-year survival. 1 Breast cancer can be categorized according to the expression of immunohistochemical surrogates [oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptors (HER) 1 and 2 and cytokeratins 5 and 6] for molecular classification. ER-positive tumours can be subcategorized into luminal A and B tumours, the former being associated with expression of PR, low proliferation markers (Ki-67), low grade and good outcomes but prone to late recurrences, while the latter is associated with high proliferation markers and high grade.
The treatment of ER-positive breast cancers has improved with the introduction of tamoxifen, a competitive inhibitor of ER, and recent reports show that aromatase inhibitors (e.g. letrozole), which inhibit the conversion of androgen to oestrogen, may be more beneficial clinically compared to tamoxifen in postmenopausal women. 2 Patients using either drug may exhibit de-novo resistance or acquired resistance, leading to endocrine therapy failure. 3 Studies have shown that 90 and 30% of patients with luminal B and luminal A tumours, respectively, exhibit high recurrence scores. 4, 5 In addition to tamoxifen and aromatase inhibitors, other therapeutic options, including Faslodex and luteinizing hormone-releasing hormone (LHRH) agonists, have been developed and are still under study. Thus, there is a continuing need to identify patients who are more likely to develop resistance and therefore provide more rigorous follow-up.
The ER-alpha (ER-a) receptor can be phosphorylated at a number of amino acid residues, including serines 118 and 167. 6, 7 Due to conflicting evidence, there is still no clear consensus on the role of phosphorylation at serines 118 (p-S118) and 167 (p-S167) in tamoxifen resistance.
The tumour microenvironment has been shown to play an important role in cancer development. Studies have shown that factors including microvessel density, lymphovascular invasion, tumour necrosis, inflammatory infiltrates, tumour stromal percentage and tumour budding are important in determining the patient's response to therapy. [8] [9] [10] [11] [12] [13] However, the relationship between p-S118/p-S167 and the tumour microenvironment has not been studied. Thus, the aims of the study are to investigate (i) the relationship between p-S118/p-S167 and the tumour microenvironment, and (ii) the effect of p-S118/167 on survival and recurrence in ER-positive primary operable ductal breast cancers. Considering the importance of the microenvironment and ER phosphorylation status, we hypothesize that these factors may have to be considered jointly in determining recurrence risk.
Materials and Methods

P A T I E N T S
Ethical approval for expression studies in human tissue samples was obtained from the West of Scotland Research Ethics Service West of Scotland REC4 (REC Ref: Project no. 02/SG007(10), R and D project: RN07PA001). Although patient consent was not obtained, all patient details were anonymized and identifiers were removed. Patients included in this study were diagnosed with operable ER-positive breast cancers at three Glasgow hospitals -The Royal Infirmary, Stobhill Hospital and Western Infirmary between 1995 and 1998 (n = 294) -and treated with adjuvant tamoxifen. Clinicopathological characteristics including age, tumour size, invasive grade in histological grade, histological tumour type, nodal status, lymphovascular invasion, type of surgery and adjuvant therapy (chemotherapy and radiotherapy) were retrieved from routine reports. Recurrences and cancer deaths were used as endpoints. The date and cause of death was confirmed by cross-checks with the Registrar General (Scotland) and the cancer registration system. Recurrences were defined as the date of first recurrence of breast cancer. Recurrence-free interval (RFI) was measured from the time of surgery until the date of first recurrence at any site. Breast cancer-specific survival (CSS) was measured from time of surgery to death due to breast cancer. Patients were followed-up regularly after surgery.
I M M U N O H I S T O C H E M I S T R Y ( I H C )
One 0.6-mm 2 core from each tumour was placed into each of three separate tissue microarray (TMA) blocks (Beecher Scientific, Silver Spring, MD, USA); 2.5-lmthick paraffin wax sections from each TMA block were mounted on silanized glass slides for IHC. ER, PR and HER-2 status were performed as described previously.
14 IHC staining on TMAs was also used to assess for Ki-67 using Dako anti-Ki67 (1:100; monoclonal mouse anti-human, Ki-67 antigen, clone MIB1, code M7240; Dako, Glostrup, Denmark) with a cut-off of 15%. 15 Terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) was scored using the point score technique, the same technique used to score Ki-67. The Klintrup-Makinen method was used to assess the generalized inflammatory infiltrate semiquantitatively. In brief, the haematoxylin and eosin (H&E)-stained sections of the deepest point of tumour invasion was used, whereby inflammatory cell density at the invasive margin was graded using a four-point scale and classified subsequently as low grade (no increase or mild/patchy increase in inflammatory cells) or high grade (prominent inflammatory reaction forming a band at the invasive margin or florid cuplike infiltrate at the invasive edge with destruction of cancer cell islands), as described previously. 16 [18] [19] [20] These were grouped according to tertiles, as there appeared to be no consistent and welldefined cut-offs. Tumour stromal percentage refers to the area of stroma in a single X10 field with tumour cells at all corners. Tumour budding refers to the detachment of single or cluster of five cancer cells in the stroma at the invasive margins of the tumour. 21 Lymphatic endothelial marker D2-40 (monoclonal antibody, SIG-3730; Covance Inc., Princeton, NJ, USA) and vascular endothelial marker factor VIII (mouse monoclonal antibody (NCL-L-Vwf; Leica, Newcastle, UK), both at 1:100 dilution, were used for IHC staining on 2.5-lm thick sections for lymph and blood vessel invasion, as described previously. 9 The tissues were first dewaxed and rehydrated. For antigen retrieval, sections were heated in sodium citrate buffer at pH 6 for 1.5 min in a pressure cooker until under pressure and then for another 5 min once pressure conditions were achieved. Following this, samples were cooled for 20 min. Blocking of endogenous peroxidase was achieved by incubation of tissue in 3% hydrogen peroxidase for 10 min. Samples were incubated in 1.5% horse serum for 30 min to block non-specific binding. Following this, the samples were incubated in the primary antibodies at 4°C overnight; p-S118 (1:500 dilution, #2511; Cell Signalling, Danvers, MA, USA) and p-S167 (1:200, #5587; Cell Signalling). The specificity of the antibodies has been shown previously. 22, 23 Phospho-ER epitopes antigenicity have been shown to be stable. 24 The slides were then washed twice in Tris-buffered saline (TBS) for 5 min before incubation in Dako EnVision TM (K5007; Dako, Copenhagen, Denmark) before washing again twice in TBS buffer for 5 min. Diaminobenzidine (SK-4100; Vector Laboratories, Burlingame, CA, USA), which was used as a chromogen, was prepared according to the manufacturer's instructions. The slides were counterstained with haematoxylin, dehydrated and mounted with DPX (Sigma-Aldrich, St. Louis, MO, USA). TMAs of breast cancer patients without linked clinical data were used as positive and negative controls for each antibody.
S L I D E S C A N N I N G A N D S C O R I N G
The stained TMAs were scanned using a Hamamatsu NanoZoomer (Welwyn Garden City, Hertfordshire, UK). SlidePath Digital Image Hub, version 4.0.1 (Tissue IA system; SlidePath, Dublin, Ireland) was used for visualization and automated cell counts. Scoring of tissues was performed by assessors blinded to clinicopathological characteristics of the patients. Samples were scored according to the weighted histoscore/H score method. 25 In brief, staining intensity was graded as negative (0), weak (1), moderate (2) and strong (3), multiplied by the percentage of cells in each category, resulting in a range of scores from 0 to 300. Two hundred and forty cores (10% of total tissue cores) were scored for nuclear p-S118 and p-S167 by one observer (KC) and an automated tissue analysis system blinded to the patient's details and each other's scores. The interclass correlation coefficient for the observer and the automated results were 0.984 and 0.978 for p-S118 and p-S167, respectively. Subsequently, SlidePath was used to score the rest of the cores. The use of automated systems has been shown to be an effective alternative to manual scoring of samples. 26 Three TMAs of different cores were examined for each tumour and the mean score was calculated from these.
S T A T I S T I C A L A N A L Y S I S
SPSS version 22 (SPSS Inc., Chicago, IL, USA) was used to perform statistical analysis. The Kaplan-Meier method was used to estimate survival (CSS) and RFI, and the log-rank test was used to assess differences between survival curves. The Cox proportional hazards model was used for univariate and multivariate survival analysis and the calculation of hazard ratios (HRs). Mortality up to March 2010 was included in the analysis and served as a censor date. The v 2 test (or v 2 test for trend, where appropriate) was used to determine the association between p-S118/p-S167 with clinicopathological data.
Results
As shown in Table 1 , the majority of patients were above 50 years of age (76.5%) and had small (<20 cm in diameter) (66.3%), grades I or II (80.7%) tumours without lymph node involvement (56.5%). Histologically, most patients were PR-positive (67.3%), HER2-negative (89.8%) and of the The relationship between expression of p-S118/p-S167, cancer-specific survival and recurrence-free interval in primary operable oestrogen receptor-positive breast cancer. Survival is plotted for patients with cancers with low/high p-S118 (A) and p-S167 (B). Recurrence is plotted for patients with cancers with low/high p-S118 (C) and p-S167 (D). P-values were calculated using the log-rank test.
luminal A subtype (64.6%). Proliferative index indicated by Ki-67 was predominantly low (70.1%), and the majority of tumours had significant inflammatory infiltrate (assessed using the Klintrup-Makinen method 16 ) (87.8%). The majority of patients were not treated with chemotherapy (71.8%) or radiotherapy (58.2%), but all patients received tamoxifen. Based on the available information on 293 patients, the patients were on tamoxifen for a median duration of 5 years [interquartile range (IQR) = 4.5-5.0 years] and a mean duration of 4.69 years. As the median was used to distinguish between low and high expression of p-S118 and p-S167 (92.5 for p-S118 and 14 for p-S167), there were approximately equal numbers of tumours with high or low p-S118 and p-S167. Figure 1 shows the immunohistochemical staining of p-S118 and p-S167 in ER-positive and -negative tumours. Although the staining intensity of p-S118 and p-S167 appears less significant than ER in the figure, this was not observed in all cases. Tables 2 and 3 show the relationship between p-S118, p-S167, tumour microenvironmental factors and clinicopathological characteristics. High p-S118 was associated with tumour size (P = 0.011) and microvessel density (P = 0.023). Similarly, high p-S167 was associated with increased microvessel density (P = 0.009), apoptotic index indicated by TUNEL (P = 0.002), general inflammatory infiltrate (P = 0.007) and CD68 + macrophage infiltrate (P = 0.010). p-S118 and p-S167 were associated strongly positively with each other (P = 0.003).
The patients were followed-up for a median of 70 months (IQR = 59-81 months) During the followup period, 46 patients experienced recurrence. At the end of follow-up 110 patients died and, of these, 48 deaths could be attributed directly to their disease. In addition to the breast cancer deaths, 15 deaths were attributed to malignant disease of other organs (including lung and colon cancer), 18 deaths were attributed to vascular diseases (including coronary heart disease and cerebrovascular disease), 16 deaths were attributed to respiratory diseases (including chronic obstructive pulmonary disease and pneumonia) and the remaining 13 deaths were caused by a variety of causes including death of unknown cause. High p-S167 was associated with significantly shorter CSS (152 months versus 170 months; P = 0.003; Figure 2B ) and RFI (91 months versus 101 months; P = 0.001; Figure 2D ) compared to tumours with low p-S167. Mean CSS (158 months versus 160 months; P = 0.507; Figure 2A ) and RFI (95 months versus 95 months; 0.443; Figure 2B ) were not significantly different in tumours with low or high expression of p-S118. When compared together, patients with high p-S167 were more associated with poorer CSS and RFI compared to p-S118 (Figure 3) . 
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High p-S167, low p-S118 The relationship between combinations of p-S118 and p-S167 with cancer-specific survival and recurrence-free interval in primary operable oestrogen receptor-positive breast cancer. P-values were calculated using the log-rank test.
Subgroup analyses were performed based on tumour subtypes luminal A and B. High p-S118 was associated with tumour size (P = 0.024), grade (P = 0.042), microvessel density (P = 0.008), general inflammatory infiltrate (P = 0.036) and the use of chemotherapy (P = 0.037) or radiotherapy (P = 0.046) in luminal A tumours and associated with blood vessel invasion (P = 0.042) in luminal B tumours. Conversely, high p-S167 was associated with PR-positive status (P = 0.032), increased microvessel density (P = 0.026), apoptotic index indicated by TUNEL (P = 0.013) and CD68 + macrophage infiltrate (P = 0.030) in luminal A tumours (Table 4) . p-S167 was not associated significantly with any clinicopathological characteristics in luminal B tumours.
Survival analyses showed that high p-S167 was associated with shorter RFI in both subtypes luminal A (92 months versus 105 months; P = 0.032; Figure 4A ) and luminal B (128 months versus 153 months: P = 0.033; Figure 4B ). The same association was seen on multivariate analysis (Table 5) ; luminal A [HR = 4.441, 95% confidence interval (CI) = 1.004-19.638, P = 0.049] and B (HR = 4.971, 95% CI = 1.386-17.834, P = 0.014). p-S118 and p-S167 were not associated with CSS in luminal A and B tumours (Table 6 ).
Discussion
Although there have been studies investigating the role of p-S118, p-S167 and the tumour microenvironment individually in determining survival, the relationship between these factors has not been investigated. The present study observed associations between both p-S118 and p-S167 and several microenvironmental factors. However, only p-S167 had power in stratifying patients according to outcome measures, as it was associated with RFI and CSS in the full cohort and with RFI in the luminal A and B tumours. This may be due to p-S167 associating with more variables associated with the tumour microenvironment.
The weighted histoscore/H score method was used in the present study. Although the IHC cut-off method and the Allred method is used by some researchers, it is accepted widely that the weighted histoscore/H score method provides more information. For example, McCarty et al. 27 recommended that this should be the method of choice for assessing ER in breast tumours. Since then, it has been adapted widely in the research field as the method of choice (although Allred is still employed clinically). More recently, Brouckaert et al. 28 discussed reasons why a quantitative assessment of the steroid receptors in breast cancer is the preferred method and that we should employ a weighted histoscore/H score method.
In addition, the weighted histoscore/H score method was employed in the TEAM (adjuvant tamoxifen and exemestane in early breast cancer) clinical trial to assess ER levels. 26, 29 The median was used as the cut-off for low and high, as it is an unbiased measure and is more informative than 1 or 10%, as employed previously by others.
In the present study, ER levels and phospho-ER levels were assessed using IHC. Ligand binding assays have been reported to provide inaccurate results due to tissues inherently being a heterogeneous mix of tumour and stromal cells. If ER or phospho-ER was assessed using ligand binding assays, results would have varied due to inconsistencies in tumour stromal Figure 4 . The relationship between expression of p-S167 and recurrence-free interval in primary operable luminal A and B oestrogen receptor-positive breast cancer. Recurrence is plotted for patients with cancers with low/high p-S167 in luminal A (A) and B (B) cancers. P-values were calculated using the log-rank test. 
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Age (≤50/>50 years) percentage between specimens. 30 Using IHC, it is clear that the expression status of ER and phospho-ER is assessed in only tumour cells.
The IHC technique allows examination of ER phosphorylation in multiple cell types (tumour and surrounding microenvironment) that make up the heterogeneous sample. In addition, the use of IHC allows us to assess expression in different cellular regions. Therefore, IHC is considered appropriate to utilize in the present study, especially as stringent antibody validation using both immunoblotting and IHC was employed.
Due to conflicting evidence, the role of p-S118 and p-S167 in tamoxifen resistance remains unclear. While p-S118 has been reported to be associated with better prognosis, a less malignant phenotype and higher response rate to tamoxifen, 22, 31 some studies have also shown its association with poorer response to endocrine therapy. 32, 33 Kirkegaard et al. showed that activated Akt (protein kinase B) is associated with relapse and death in ER-a positive, tamoxifen-treated patients, thus suggesting that p-S167 may be associated with worse disease outcome, while Yamashita et al. 33, 34 showed that p-S167 was predictive of response to endocrine therapy and longer survival after relapse. This study reports that high p-S167 is associated with poor prognosis and higher microvessel density, apoptotic index and macrophage infiltrate, all of which are associated with poorer prognosis, 8, 35, 36 thus supporting the association of p-S167 with poorer outcomes. Given these associations, p-S167 may be involved with signalling pathways associated with inflammatory cytokine release. Future studies should focus upon identifying these pathways, as they may be useful therapeutic targets.
Svensson et al. 37 showed that high serum oestradiol levels were associated with high levels of extracellular CCL2 and CCL5 in vivo, inducing infiltration of tumour-associated macrophages. Similarly, the role of oestradiol in the recruitment and activation of macrophages has also been shown in ovarian cancer. 38 These studies support our findings that ER activation is associated with macrophage infiltration, both of which are associated with poorer prognosis.
p-S167 was found to be a predictor of a shorter RFI in both luminal A and B cancers and was also associated with higher microvessel density, apoptotic index and macrophage infiltration in luminal A tumours. This suggests that luminal A tumours can be subcategorized further into two groups by p-S167 status. Although patients with luminal A tumours have a good prognosis, in this study the difference in RFI between patients with high and low expression of p-S167 was approximately 1 year. Therefore, identification of these patients using p-S167 for more rigorous treatment may be clinically useful. Luminal B tumours have been known to have a more aggressive phenotype, thought to be due to the up-regulation of HER2, leading to the up-regulation of Akt and mitogen-activated protein kinase (MAPK) pathways. As p-S167 is associated with these pathways, p-S167 may be important in stratifying patients with luminal B tumours. Replication of our findings in a larger cohort, such as the TEAM trial, would establish the utility of p-S167 as an important biomarker for stratifying patients in future clinical trials.
In recent years, increasing number of patients undergo 'switch therapy' (a sequential switch to aromatase inhibitors after tamoxifen) or have extended treatments of up to 10 years of tamoxifen or aromatase inhibition. It may be hypothesized that such a switch of strategies would have an effect on levels of p-S118 and p-S167. However, given that such a strategy was not ongoing at the time of recruitment of the patient cohort, it was not possible to address this hypothesis.
Recently, studies have shown that recurrent ESR1 mutations within the ligand binding domain in ER-positive endocrine-resistant metastatic breast cancer were identified at higher frequencies in patients who received multiple hormonal treatments, suggesting that the mutations result in increased ER activity and thus increased tumour growth, presenting as a clinical relapse. 39, 40 As p-S167 is associated with a shorter RFI, it would be interesting to examine the relationship between p-S167 mutation and LBD mutations of ESR1. Also, as LBD mutations are relatively uncommon in treatment-naive patients, it would be of interest to examine these mutations in patients who have already received multiple hormonal treatments.
Conclusion
In summary, this study showed the utility of p-S118 and p-S167 in stratifying patients' risk of relapse and the relationship between p-S118 and p-S167 and the tumour microenvironment. As p-S167 was associated with RFI and CSS in the whole cohort and RFI in luminal A and B tumours, p-S167 may be an important biomarker for stratifying patients in future. 
